Atul Batra

Dr
New Delhi, DL, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 146 publications

Childhood Cancer Survival Outcomes in India: A Scoping Review of Three Decades of Survival Data for Policy Insights.

Childhood Cancer Survival Outcomes in India: A Scoping Review of Three Decades of Survival Data for Policy Insights.

Journal: JCO global oncology

Published: July 17, 2026

Socioeconomic Outcomes of Childhood Cancer Survivors in India: A Cross-Sectional Study From a Tertiary Care Childhood Cancer Survivorship Program.

Socioeconomic Outcomes of Childhood Cancer Survivors in India: A Cross-Sectional Study From a Tertiary Care Childhood Cancer Survivorship Program.

Journal: JCO global oncology

Published: July 01, 2026

Cost-effectiveness analysis of fosaprepitant versus aprepitant-based antiemetic regimens in children receiving highly emetogenic chemotherapy: individual patient-level analysis of a randomised trial.

Cost-effectiveness analysis of fosaprepitant versus aprepitant-based antiemetic regimens in children receiving highly emetogenic chemotherapy: individual patient-level analysis of a randomised trial.

Journal: BMJ supportive & palliative care

Published: May 02, 2026

Integrated Genomic Profiling of Newly Diagnosed and Relapsed Acute Myeloid Leukemia Identifies Driver Genes, Mutational Signatures, and Therapeutic Targets.

Integrated Genomic Profiling of Newly Diagnosed and Relapsed Acute Myeloid Leukemia Identifies Driver Genes, Mutational Signatures, and Therapeutic Targets.

Journal: Cancers

Published: March 28, 2026

Preventing Hand-Foot Syndrome in Patients With Cancer: A Systematic Review and Network Meta-Analysis.

Preventing Hand-Foot Syndrome in Patients With Cancer: A Systematic Review and Network Meta-Analysis.

Journal: JAMA dermatology

Published: March 04, 2026

Lymph Node Ratio as an Independent Prognostic Factor in Breast Cancer: A Retrospective Study of 4060 Patients Undergoing Axillary Lymph Node Dissection.

Lymph Node Ratio as an Independent Prognostic Factor in Breast Cancer: A Retrospective Study of 4060 Patients Undergoing Axillary Lymph Node Dissection.

Journal: Clinical breast cancer

Published: January 11, 2026

pH-responsive dual-drug-loaded bovine serum albumin nanoparticles for targeted cancer therapy.

pH-responsive dual-drug-loaded bovine serum albumin nanoparticles for targeted cancer therapy.

Journal: International journal of biological macromolecules

Published: January 10, 2026

Psychosocial Distress, Social Support, and Sexual Health Among Adult Survivors of Childhood Cancer in India: Findings From the Childhood Cancer Survivorship Program.

Psychosocial Distress, Social Support, and Sexual Health Among Adult Survivors of Childhood Cancer in India: Findings From the Childhood Cancer Survivorship Program.

Journal: Pediatric blood & cancer

Published: January 04, 2026

Association of longitudinal changes in nutritional status with survival outcomes in childhood cancer.

Association of longitudinal changes in nutritional status with survival outcomes in childhood cancer.

Journal: Clinical nutrition (Edinburgh, Scotland)

Published: November 28, 2025

A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC).

A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 10, 2025

A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC).

A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 10, 2025

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2-Positive Early, Locally Advanced, and Oligometastatic Breast Cancer: Real-World Outcomes From India.

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2-Positive Early, Locally Advanced, and Oligometastatic Breast Cancer: Real-World Outcomes From India.

Journal: JCO global oncology

Published: November 05, 2025

Showing 1-12 of 146

Last Updated: 09/26/2026